Radiopharmaceuticals

Male patient with doctor
#Archeus Technologies #Clinical trial #Prostate cancer #Radiopharmaceuticals

First patient dosed in Phase I trial of prostate cancer drug 

The first patient has been dosed in the Phase I clinical trial of ART-101 in men with metastatic castration-resistant prostate cancer (mCRPC).  ART-101 is a novel receptor-based targeting small molecule developed for the imaging and treatment of prostate cancer. The therapy targets prostate-specific membrane antigen (PSMA) and,… Read More

#Cancer Research #News

#Drug discovery #Oncology #Radiopharmaceuticals #Theranostics

The promise of therapeutic radiopharmaceuticals

Denis R Beckford-Vera, Head of Radiopharmacology at Champions Oncology explores how radiopharmaceuticals can benefit from the use of patient-derived xenograft models.  The rising promise of radiopharmaceuticals Targeted radionuclide therapies (TRTs) are rapidly becoming a major force in oncology drug development. These agents combine a tumour-targeting molecule with a radioactive isotope,… Read More

#Exclusive Content

Radioactive containers
#Collaboration #Crown Bioscience #Medicines Discovery Catapult #Radiopharmaceuticals

MDC and Crown Bioscience collaborate on radiopharmaceutical innovation 

Medicines Discovery Catapult (MDC) and Crown Bioscience have announced a collaboration to deliver an integrated translational biology platform for companies developing radiopharmaceuticals.   The global collaboration between MDC and Crown Bioscience will support companies across the radiopharmaceutical pipeline, whether they are advancing radiotherapeutics, exploring new isotopes, or optimising targeting agents.  The… Read More

#Business & Investment #News

#Cancer research #Drug discovery #Personalised medicine #Perspective Therapeutics #Radiopharmaceuticals

New podcast: Redefining oncology with radiopharmaceuticals

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Thijs Spoor, CEO… Read More

#News

#Actithera #Financing #Radioligand Therapies (RLTs) #Radiopharmaceuticals

Actithera raises $75.5m to support its precision radioligand therapies

Radiopharmaceutical biotech company Actithera has closed an oversubscribed $75.5 million Series A financing round.   The financing will support the advancement of Actithera’s lead fibroblast activation protein (FAP)-targeting asset into clinical development in multiple indications, while also enabling the continued development of its radioligand therapies (RLT) discovery platform and preclinical pipeline. … Read More

#Business & Investment #News

Prostate cancer cells
#Archeus Technologies #FDA #Oncology #Phase I trial #Prostate cancer #Radiopharmaceuticals

FDA clears radiopharmaceutical for prostate cancer

The US Food and Drug Administration (FDA) has cleared Archeus Technologies’ Investigational New Drug (IND) application for ART-101, a novel receptor-based targeting small molecule for the imaging and treatment of prostate cancer.   This clearance enables the company to initiate a Phase I clinical trial in men with metastatic castration-resistant prostate… Read More

#Cancer Research #News #Regulatory

#Mergers and acquisitions #Oncology #Prostate cancer #Radiopharmaceuticals #RayzeBio

RayzeBio buys prostate cancer radiopharmaceutical for $1.35bn

Philochem and RayzeBio, a subsidiary of Bristol-Myers Squibb, have announced a definitive agreement under which RayzeBio will purchase the exclusive worldwide rights to prostate cancer therapeutic OncoACP3.  OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in prostate cancer.   The… Read More

#Business & Investment #News

Theranostic radiopharmaceuticals
#Oncology #Radiochemistry #Radiopharmaceuticals

New standard ensures accurate dosing of radiopharmaceuticals

Scientists at the National Institute of Standards and Technology (NIST) have developed the first US standard for measuring the radioactivity of actinium-225, a radioactive isotope that drug companies are using to develop a new class of anticancer drugs.  The new standard, which is tied to the International… Read More

#Cancer Research #News

Neuroendocrine tumours
#ASCO #Clinical trial #Oncology #Perspective Therapeutics #Radiopharmaceuticals

Perspective shares positive responses in NETs at ASCO

Perspective Therapeutics has shared interim results from its ongoing Phase I/IIa clinical trial of [212Pb]VMT-α-NET at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.  The Phase I/IIa clinical trial is a multi-centre open-label dose escalation and dose expansion study of [212Pb]VMT-α-NET in patients with unresectable… Read More

#Cancer Research #News

#Cancer therapeutics #Cancer vaccine #CAR-T #Oncology #Radiopharmaceuticals

New DDW Highlights episode: 10 February 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Following World Cancer Day on 4 February, the news round-up this week focuses on… Read More

#News

#Cancer therapeutics #Cancer vaccine #CAR-T #Oncology #Radiopharmaceuticals

This week in drug discovery (3-7 February) 

News round-up for 3-7 February by DDW Senior Digital Content Editor Diana Spencer. Following World Cancer Day on 4 February, the news round-up this week focuses on new approaches to the treatment of cancer, including radiopharmaceuticals, programmable cell depletion and preventative vaccines. The top stories:… Read More

#News

Small cell lung cancer
#Ariceum Therapeutics #FDA #Lung cancer #Oncology #Orphan drugs #Radiopharmaceuticals

Radiopharmaceutical cancer therapy granted orphan drug status

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Ariceum Therapeutics’ 225Ac-SSO110 (satoreotide) for the treatment of patients with small cell lung cancer (SCLC).  Ariceum has announced plans to commence Phase I/II human clinical development of 225Ac-satoreotide under the trial name, SANTANA-225 in Q1 2025. … Read More

#News #Regulatory

#Artificial intelligence (AI) #Cancer research #Immunotherpy #Oncology #Radiopharmaceuticals #Therapeutic Antibodies

What lies ahead in cancer research?

Megan Thomas comments and speaks with experts to uncover the future of cancer research. Artificial intelligence (AI) It’s not whether AI should be used, it’s when and how. Until several hurdles are overcome, such as data quality, data privacy and security, as well as regulatory and ethical challenges, this is… Read More

#Cancer Research #Exclusive Content

#Financing #Oncology #Radioligand Therapies (RLTs) #Radiopharmaceuticals #Starget Pharma #Start-ups

Starget secures $5.1m for clinical trial of targeted cancer therapy

Start-up Starget Pharma has raised $5.1 million in funding to support development of its radioligand-based therapies that target tumour cells with focused radiation. The investment was secured from Cancer Focus, a fund established in collaboration with the MD Anderson Cancer Center at the University of Texas. The funds will support… Read More

#Business & Investment #News #Start-up Zone

Radioactive containers
#Affibody #Nuclear medicine #Oncology #Preclinical investigations #Radiopharmaceuticals

Preclinical data shows efficacy of radio-therapeutic anti-HER2 agent

Affibody has shared the results of preclinical studies with its radiotherapeutic agent 177Lu-ABY-271 for treatment of HER2-expressing metastatic disease. The data were presented at the Annual Congress of the European Association of Nuclear Medicine by investigator Yongsheng Liu in the Professor Tolmachev group, Uppsala University. Read More

#Cancer Research #News

Radioactive containers
#Akiram Therapeutics #Events #Immunotherapy #Oncology #Radiopharmaceuticals

Radioimmunotherapy drug results to be shared at EANM

Akiram Therapeutics will reveal its research findings on radioimmunotherapy drug candidate AKIR001 at the European Association of Nuclear Medicine (EANM) Congress 2024 in Hamburg, from 19-23 October. 177Lu-AKIR001 holds the potential to become a first-in-class treatment in multiple cancer types, including anaplastic and iodine-refractory thyroid cancer,… Read More

#News